Effective March 1, 2019, the Agency for Health Care Administration (Agency) entered into a contract with CVS Caremark (Vendor) to fulfill the responsibilities of the Statewide Medicaid Comprehensive Hemophilia Management Program. The Vendor’s contract combines the provision of pharmaceutical products, pharmaceutical management, and disease management (e.g., treatment and prevention of bleeding episodes, medical consultation, home infusion education, training, twenty-four hours per day, seven days a week access to a registered nurse and a licensed pharmacist) for the Florida Medicaid recipients diagnosed with hemophilia or Von Willebrand disease.
Through the Statewide Medicaid Comprehensive Hemophilia Management Program, the Agency will assure eligible recipients access to all products related to factor replacement therapy available.
Hemophilia drugs are an excluded service from the health plans benefit package. They are covered through the fee-for-service Statewide Medicaid Comprehensive Hemophilia Disease Management Program. Though not a covered benefit through the Statewide Medicaid Managed Care Program, health plans are required to coordinate the care of its enrollees who require services covered outside of the managed care delivery system.